Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer

Gynecologic Oncology

Volumn 67, Issue 3, 1997, Pages 272-276

  Morgan, Mark A ^a,b   Stadtmauer, Edward A ^a   Luger, Selina M ^a   Porter, David L ^a   Mangan, Patricia A ^a   O'Neil, Patricia ^a   Kamelle, Scott ^a   Benjamin, Ivor ^a   Mick, Rosemarie ^a   King, Stephanie A ^a   Rubin, Stephen C ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b Division of Gynecologic Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; PLATINUM DERIVATIVE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GYNECOLOGIC CANCER; HUMAN; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 17444448726     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4878     Document Type: Article

References (27)

1. 1. Kotz KW, Schilder RJ: High-dose chemotherapy and hematopoietic progenitor cell support for patients with epithelial ovarian cancer. Semin Oncol 22:250-262, 1995
2. 2. Shpall EJ, Stemmer SM, Bearman SI, Bast RC Jr., Peters WP, Ross M, Jones RB: High-Dose Chemotherapy with Autologous Bone Marrow Support for the Treatment of Epithelial Ovarian Cancer, in Markman M, Hoskins WJ (eds): Cancer of the Ovary. New York, Raven Press, 1993, pp 327-338
3. 3. Markman M, Hoskins WJ: Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 10:513-514, 1992 (editorial)
4. 4. Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P, Tarbell N, Coral F, Daley H, Yeap B, Schlossman SF, Nadler LM: Prolonged disease free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphomas with poor prognosis. N Engl J Med 316:1499-1515, 1987
5. 5. Antman K, Gale RP: Advanced breast cancer: High dose chemotherapy and bone marrow autotransplants. Ann Int Med 108:570-574, 1988
6. 6. Bonadonna G, Valagussa P, Santoro A: Alternating non-crossresistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Int Med 104:739-746, 1986
7. 7. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, DeVita VT Jr: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
8. 8. Einhorn LH, Donohue J: Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Int Med 87:293-298, 1977
9. 9. Gianni AM, Bregni M, Siena S, Lombardi F, Gandola L, Valagussa D, Bonadonna G: Prospective randomized comparison of MACOP-B vs. rhGM-CSF supported high-dose sequential myeloablative chemotherapy in diffuse large cell lymphomas. Proc Am Soc Clin Oncol 10:274, 1991 (abstract)
10. 10. Lotz JP, Machover D, Malassagne B, Hinge B, Donsimoni R, Gumus Y, Gerota J, Lam Y, Tulliez M, Marsiglia H, Mauban S, Izrael V: Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J Clin Oncol 9:1860-1870, 1991
11. 11. Shea TC, Mason JR, Stoniolo AM, Newton B, Breslin M, Mullin M, Ward DM, Miller L, Christian M, Taetle R: Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusion of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 10:464-473, 1992
12. 12. Tepler I, Cannistra SA, Frei E 3rd, Gonin R, Anderson KC, Niloff J, Goodman H, Muntz H, Muto M, Sheets E, Elias AD, Mazanet R, Wheeler C, Ayash L, Schwartz G, McCauley M, Gaynes L, Harvey S, Schnipper LE, Antman KH: Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 11:1583-1591, 1993
13. 13. Crown J, Wasserheit C, Hakes T, Fennelly D, Reich L, Moore M, Schneider J, Curtin J, Rubin SC, Reichman B, Moore M, Yao TJ, Gilewski T, Gulati S, Markman M, Norton L: Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral-blood derived hematopoietic progenitor cells. J Natl Cancer Inst 84:1935-1936, 1992
14. 14. Schabel FM, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH: Establishment of cross resistant profiles for new agents. Cancer Treat Rep 67:905-922, 1983
15. 15. Levin L, Hryniuk W: Dose intensity analysis of chemotherapy regimens in ovarian cancer. J Clin Oncol 5:756-767, 1987
16. 16. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E 3rd, Henner WD: A phase I clinical and pharmacological study of high-dose carboplatin and autologous bone marrow support. J Clin Oncol 7:651-661, 1989
17. 17. Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP: Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:18-24, 1994
18. 18. Kohn E, Reed E: Controversies in the treatment of advanced ovarian cancer. NIH Catalyst, May 1994, pp 17-22
19. 19. Bartner JF, Barnes WA: Second-Look Laparotomy, in Rubin SC, Sutton, GP (eds): Ovarian Cancer. New York, McGraw-Hill, 1993, pp 269-300
20. 20. Markman M, Reichman B, Hakes T, Lewis JL Jr, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W: Impact on survival of surgically defined favorable responses to salvage with intraperitoneal chemotherapy in small volume residual ovarian cancer. J Clin Oncol 10:1478-1484, 1992
21. 21. ten Bokkel Huinink WW, Dubbleman R, Aartsen E, Franklin H, McVie JG: Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol 12:(suppl 4) 43-46, 1985
22. 22. Rubin SC: Second-Look Laparotomy in Ovarian Cancer, in Markman M, Hoskins WJ (eds): Cancer of the Ovary. New York, NY, Raven Press, 1993, pp 175-185
23. 23. Ozols R, Rubin S, Thomas G, Robboy SJ: Epithelial Ovarian Cancer, in Hoskins W, Perez C, Young RC (eds): Principles and Practice of Gynecologic Oncology, 2nd ed, Philadelphia, Lippincott-Raven, 1997, pp 919-986
24. 24. McGowan L: Patterns of care in carcinoma of the ovary. Cancer 71:628-633, 1993
25. 25. O'Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire WP III, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK: Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study. J Clin Oncol 15: 177-186, 1997
26. 26. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC: Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14:3074-3084, 1996
27. 27. Reed E, Sarosy G, Kohn E, Christian M, Link CJ Jr, Goldspiel B, Davis P, Jacob J, Maher M: A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary. Gynecol Oncol 61(3):349-353, 1996